Suppr超能文献

一个与轴突导向相关的微小RNA检测面板可识别胰腺癌患者根治性手术后的血管周围丛局部复发。

An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer.

作者信息

Nishiwada Satoshi, Nakamura Kota, Ozu Naoki, Terai Taichi, Kohara Yuichiro, Nagai Minako, Sakata Takeshi, Doi Shunsuke, Matsuo Yasuko, Yasuda Satoshi, Tanaka Toshihiro, Sho Masayuki

机构信息

Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.

Department of Surgery, Minami-Nara General Medical Center, Nara, Japan.

出版信息

J Gastroenterol. 2025 May 10. doi: 10.1007/s00535-025-02260-w.

Abstract

BACKGROUND

Complete oncological local control is essential for a potential cure in patients with pancreatic ductal adenocarcinoma (PDAC), but predicting local recurrence following curative surgery remains clinically challenging. In this study, we performed comprehensive biomarker discovery to identify an Axon guidance-related miRNA panel (AGMP) for risk-stratification of perivascular plexus recurrence (PPR) following curative surgery in patients with PDAC.

METHODS

To identify axon guidance-related microRNAs, we performed the pathway-miRNA interaction analysis using the miRPathDB2.0. Subsequently, the predictive performance of the miRNAs was trained and validated in three independent clinical surgically resected sample cohorts and one pretreatment blood sample cohort with different disease statuses [upfront surgery cohort: n = 162 (training: n = 103, internal validation: n = 59), neoadjuvant chemoradiotherapy (NACRT) cohort: n = 217, arterial invasion cohort: n = 62, pretreatment blood sample cohort: n = 53].

RESULTS

The pathway-miRNA interaction analysis identified 13 miRNAs related to axon guidance pathway. Subsequently, we trained a 13-miRNA risk-prediction model, AGMP, which robustly distinguished PPR after surgery in the training cohort (AUC = 0.95). The AGMP was successfully validated in three independent cohorts (AUC: validation = 0.94, NACRT = 0.94, Arterial invasion = 0.90). Furthermore, we additionally validated the performance of AGMP in a pretreatment blood cohort, which again confirmed the robustness of risk-stratification for PPR (AUC = 0.86).

CONCLUSIONS

We developed a novel biomarker, AGMP that demonstrated remarkable predictive performance for PPR following curative surgery in patients with PDAC; highlighting the clinical importance of the nerve-cancer cross-talk and the hopefulness as a guidepost for designing future clinical and basic research to establish individualized treatment strategies.

摘要

背景

完整的肿瘤学局部控制对于胰腺导管腺癌(PDAC)患者的潜在治愈至关重要,但预测根治性手术后的局部复发在临床上仍然具有挑战性。在本研究中,我们进行了全面的生物标志物发现,以确定一个轴突导向相关的miRNA面板(AGMP),用于对PDAC患者根治性手术后血管周围丛复发(PPR)进行风险分层。

方法

为了鉴定轴突导向相关的微小RNA,我们使用miRPathDB2.0进行了通路-miRNA相互作用分析。随后,在三个独立的临床手术切除样本队列和一个具有不同疾病状态的预处理血液样本队列中对这些miRNA的预测性能进行了训练和验证[ upfront手术队列:n = 162(训练:n = 103,内部验证:n = 59),新辅助放化疗(NACRT)队列:n = 217,动脉侵犯队列:n = 62,预处理血液样本队列:n = 53]。

结果

通路-miRNA相互作用分析确定了13个与轴突导向通路相关的miRNA。随后,我们训练了一个13-miRNA风险预测模型AGMP,该模型在训练队列中能够有力地区分术后的PPR(AUC = 0.95)。AGMP在三个独立队列中成功得到验证(AUC:验证 = 0.94,NACRT = 0.94,动脉侵犯 = 0.90)。此外,我们还在预处理血液队列中验证了AGMP的性能,再次证实了其对PPR风险分层的稳健性(AUC = 0.86)。

结论

我们开发了一种新型生物标志物AGMP,它在PDAC患者根治性手术后对PPR表现出显著的预测性能;突出了神经-癌症相互作用的临床重要性,以及作为设计未来临床和基础研究以建立个体化治疗策略的指导的希望。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验